Pharmaceutical

J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis

Johnson & Johnson Innovation Medicine has submitted a request to the FDA to approve Tremfya as a treatment for ulcerative colitis.

Nov 23, 2024 - 06:00
J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis
Johnson & Johnson Innovation Medicine has submitted a request to the FDA to approve Tremfya as a treatment for ulcerative colitis.
Read the original article

Tags:

Previous Article

UK point-of-care production of cell therapies could arrive in 2025

Next Article

“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NPX-267 by NextPoint Therapeutics for Renal Cell Carcinoma: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Renal Cell Carcin...

Jun 14, 2024

Apollo Therapeutics secures $226.5m to advance pipeline programmes

Apollo Therapeutics secures $226.5m to advance pipeline...

Sep 7, 2023

STAT+: Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion, a deal that could expand Wegovy production

STAT+: Novo Holdings to purchase drug manufacturer Cata...

Feb 5, 2024